TRANSGENE news, videos and press releases
For more news please use our advanced search feature.
TRANSGENE - More news...
TRANSGENE - More news...
- Availability of Transgene's 2023 Universal Registration Document
- Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- Transgene Announces Upcoming Investor Meetings
- Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
- Transgene Announces Financial Calendar for 2024
- Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
- Transgene: Balance Sheet of the Liquidity Contract with Natixis Oddo BHF SCA as of June 30, 2023
- Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
- Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
- Transgene provides business update and Q1 2023 financial position
- Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
- Transgene’s Combined General Meeting of May 5, 2023
- Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
- Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
- Availability of Transgene’s 2022 Universal Registration Document
- Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- Transgene Announces Upcoming Investor Meetings
- Transgene: 2022 Full-year Results and Business Update
- Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
- Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of December 31, 2022
- Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- Transgene Announces Financial Calendar for 2023
- Transgene Announces Upcoming Investor Meetings